SCHEMBL4050628

SCHEMBL4050628

Nc1cc(-c2ccnc(N)c2N)c(-c2cccs2)nc1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
CDK5 Q00535 1/20 0.42
CDK5R1 Q15078 1/20 0.42
ADK P55263 2/20 0.40
ADORA2A P29274 5/20 0.40
ADORA1 P30542 4/20 0.40
PIM1 P11309 1/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 2/20 0.40
ATM Q13315 1/20 0.40
DHFR P00374 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2495572 0.79 KDM4E (0.50) ALDH1A1KDM4ECDK5CDK5R1ADORA2A
SCHEMBL4050621 0.79 ADK (0.48) ALDH1A1KDM4EADKADORA2AADORA1
SCHEMBL4049446 0.74 MEN1 (0.42) ALDH1A1KDM4ECDK5CDK5R1ADORA2A
SCHEMBL4049734 0.73 FYN (0.42) KDM4EADORA2AADORA1MEN1KMT2A
SCHEMBL11903852 0.73 ALDH1A1 (0.44) ALDH1A1KDM4ECDK5CDK5R1NPC1
SCHEMBL11903939 0.73 ALDH1A1 (0.44) ALDH1A1KDM4ECDK5CDK5R1NPC1
SCHEMBL3792272 0.72 ADORA2A (0.33) ADORA2AADORA1HPGDADORA2B
SCHEMBL17555821 0.70 CDK5 (0.53) ALDH1A1KDM4ECDK5CDK5R1ADORA2A
SCHEMBL3786302 0.69 MAP4K4 (0.35) ADORA2AADORA1MEN1KMT2ACYP1A2
SCHEMBL16600073 0.65 KCNH2 (0.55) ALDH1A1KDM4EADORA2AADORA1PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-22 US claimed
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-22 US disclosed
EP-1735310-A1 CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma, S.A. (ES) 2006-12-27 EP disclosed
WO-2005100353-A1 CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA, SA (ES) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists ADORA2B, ADORA2A, ADORA1 ALDH1A1 621/4885KDM4E 4381/4885CDK5 1173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.